BioMedNewsBreaks – RYAH Group Inc.’s (CSE: RYAH) RYAH Medtech Expands Business Development Team

May 13, 2021 10:53:13

RYAH Group’s (CSE: RYAH) wholly owned subsidiary, RYAH Medtech Inc., has welcomed four new members to its business development team, namely Steven Schultz, Warren Thompson, Mitchell Zimmer, and Andrea Ferrari. According to the update, the newly added experts bring extensive experience and expertise in the medical and pharmaceutical industry. The team will focus on expanding RYAH’s presence in multiple verticals within the North America plant-based and nutraceutical markets, including participation in clinical trials for the company’s connected devices and custom software solutions in data analytics. “We are thrilled to announce these new appointments. This team has deep acumen in the medical device and related industries, which will allow us to capitalize on the changing regulatory environment and to bring this experience to an even wider group of clinical, medical and pharmaceutical clients worldwide,” said Gregory Wagner, CEO of RYAH and RYAH Medtech.

To view the full press release, visit

About RYAH Group Inc.

RYAH is a big data and technology company focused on valuable predictive analysis in the global medical intake industry. The company manages a complete digital ecosystem leveraging both internet of things (“IoT”) and artificial intelligence (“AI”) to create a dynamic data service for the medical plant industry. It is developing a suite of IoT devices, including a dry-herb vaporizer device capable of storing all plant lab results, measuring patient inhalation sessions in real-time and capturing instant feedback for plant dose management. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant medical data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is also relevant for pharmacies, clinics, growers, dispensaries, and licensed processors (“LPs”) to monitor and manage plant strain effects on patients. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete medical plant lifecycle, from seed to consumption. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork